KALA BIO (KALA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Jan, 2026Related party transactions
Entered into a settlement with Baker Bros. Advisors LP, issuing 900,000 shares to resolve claims related to participation rights under prior financing arrangements; Baker Bros. now beneficially owns 5,407,359 shares as of December 30, 2025.
Baker Bros. granted an irrevocable proxy to vote settlement and specified shares in line with board recommendations for six months.
Settled payment obligations to LifeSci Capital LLC by issuing 2,200,000 shares of Common Stock for financial advisory services.
Shareholder rights and capital structure
Number of outstanding shares updated to 27,849,725 as of December 30, 2025, reflecting new issuances and settlements.
Voting matters and shareholder proposals
Supplement deemed solicitation material for votes on matters described in the Proxy Statement for the 2025 Annual Meeting.
Directors, executive officers, and employees may be considered participants in proxy solicitation for stockholder approvals.
Latest events from KALA BIO
- Registering 241M+ shares for resale amid Nasdaq compliance risks and leadership changes.KALA
Registration Filing10 Feb 2026 - KPI-012's phase II-B trial for PCED targets a major unmet need, with data expected Q1 2025.KALA
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference2 Feb 2026 - All proposals, including director elections and share increase, passed unanimously.KALA
AGM 20262 Feb 2026 - KPI-012 nears phase IIb readout for PCED, targeting broad unmet needs in rare eye diseases.KALA
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - David Lazar's executive experience highlighted as board nomination is updated for the 2025 meeting.KALA
Proxy Filing26 Jan 2026 - Phase IIb trial for a novel secretome therapy in PCED targets broad approval and billion-dollar market.KALA
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Proxy seeks approval for director elections, share issuance, capital changes, and auditor ratification.KALA
Proxy Filing30 Dec 2025 - Late-stage trial for a stem cell-based eye drop targets broad PCED market with imminent data.KALA
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025 - Virtual meeting to vote on directors, compensation, auditor, share issuances, and capital changes.KALA
Proxy Filing19 Dec 2025